News and events
Select providers now have access to Haystack MRD® via OncoEMR MPI capability
We are excited to announce the launch of a pilot program between Haystack MRD® by Quest Diagnostics® and OncoEMR! Select providers now have access to Haystack MRD via OncoEMR MPI capability – meaning that you may be able to order
Haystack MRD® receives New York State approval
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has officially approved Haystack MRD® for use in identifying residual or recurring disease in patients with solid tumor cancers.
Precision Oncology Exchange with Dr TJ Slavin
The Precision Oncology Exchange with TJ is a new webinar series that serves as an interactive Q&A forum designed to explore recent oncology research and real-world clinical applications.
Webinar: How ctDNA can assist in critical nonoperative management decisions
Watch an in-depth discussion with Dr Andrea Cercek, lead author of the study, and Dan Edelstein, Vice President and General Manager of Haystack Oncology at Quest Diagnostics, exploring how these results are reshaping cancer care—and what they mean for patients,
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Haystack MRD® test for identifying MRD-positive patients with stage II colorectal
Recent events
Bringing Confidence to ASCO 2026
We’re proud to be part of the 2026 American Society of Clinical Oncology (ASCO®) annual meeting, where we’ll present 2 posters featuring new clinical data using Haystack technology.
Join us at the 2026 COA Conference
We’re excited to participate in the 2026 Community Oncology Conference by the Community Oncology Alliance (COA), where leading experts will gather to advance care for cancer patients through science and
Advancing gynecologic cancer care with exceptionally accurate MRD testing
We’re excited to host a booth at the 2026 SGO Annual Meeting on Women’s Cancer®. The Haystack MRD® team invites you to join us in San Juan for this important